Outcomes in patients with hrTA-TMA treated with eculizumab. Survival in HSCT recipients with hrTA-TMA treated with the terminal complement blocker eculizumab was calculated using Kaplan–Meier and log-rank tests starting at the beginning of HSCT (day 0, stem cell infusion day). (A) One-year post-HSCT survival in all treated patients was 66%. (B) One-year post-HSCT survival in patients with GI bleeding and without was 44% vs 78% (P = .01).